Phase Ib study of sabatolimab (<scp>MBG453</scp>), a novel immunotherapy targeting <scp>TIM‐3</scp> antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

Published:2023-11-22 Issue:2 Volume:99 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Brunner Andrew M.¹^ORCID,Esteve Jordi²,Porkka Kimmo³,Knapper Steve⁴,Traer Elie⁵,Scholl Sebastian⁶,Garcia‐Manero Guillermo⁷^ORCID,Vey Norbert⁸^ORCID,Wermke Martin⁹,Janssen Jeroen J. W. M.¹⁰,Narayan Rupa¹,Fleming Shaun¹¹,Loo Sun¹¹,Tovar Natalia²,Kontro Mika³,Ottmann Oliver G.⁴,Naidu Purushotham¹²,Sun Haiying¹²,Han May¹³,White Roisin¹⁴,Zhang Na¹⁵,Mohammed Anisa¹²,Sabatos‐Peyton Catherine A.¹⁶,Steensma David P.¹⁵,Rinne Mikael L.¹⁷,Borate Uma M.⁵,Wei Andrew H.¹⁸^ORCID

Affiliation:

1. Massachusetts General Hospital Boston Massachusetts USA

2. Hospital Clínic Barcelona Spain

3. Helsinki University Hospital Comprehensive Cancer Center Helsinki Finland

4. School of Medicine Cardiff University Cardiff UK

5. Oregon Health & Science University Portland Oregon USA

6. University Hospital Jena Jena Germany

7. MD Anderson Cancer Center Houston Texas USA

8. Institut Paoli‐Calmettes Marseille France

9. TU Dresden, NCT/UCC Early Clinical Trial Unit Dresden Germany

10. Amsterdam University Medical Centers Amsterdam The Netherlands

11. The Alfred Hospital Melbourne Victoria Australia